Akso Health Group (NASDAQ:AHG) Soars 95% This Week, Taking One-year Gains to 268%

Akso Health Group (NASDAQ:AHG) Soars 95% This Week, Taking One-year Gains to 268%

Akso Health Group(纳斯达克股票代码:AHG)本周飙升95%,使一年的涨幅达到268%
Simply Wall St ·  05/24 09:45

Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! For example, the Akso Health Group (NASDAQ:AHG) share price has soared 268% in the last 1 year. Most would be very happy with that, especially in just one year! And in the last week the share price has popped 95%. In contrast, the longer term returns are negative, since the share price is 14% lower than it was three years ago.


Since the stock has added US$89m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.


Akso Health Group wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

Akso Health Group在过去十二个月中没有盈利,我们不太可能看到其股价与每股收益(EPS)之间存在很强的相关性。可以说,收入是我们的下一个最佳选择。无利可图的公司的股东通常希望强劲的收入增长。一些公司愿意推迟盈利以更快地增加收入,但在这种情况下,人们希望良好的收入增长来弥补收益不足。

Akso Health Group actually shrunk its revenue over the last year, with a reduction of 87%. So we would not have expected the share price to rise 268%. This is a good example of how buyers can push up prices even before the fundamental metrics show much growth. Of course, it could be that the market expected this revenue drop.

实际上,Akso Health Group的收入比去年减少了87%。因此,我们没想到股价会上涨268%。这是一个很好的例子,说明买家甚至在基本面指标显示出大幅增长之前就可以推高价格。当然,可能是市场预期的收入下降。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).


NasdaqCM:AHG Earnings and Revenue Growth May 24th 2024
纳斯达克股票代码:AHG 收益和收入增长 2024 年 5 月 24 日

Take a more thorough look at Akso Health Group's financial health with this free report on its balance sheet.

通过这份免费的资产负债表报告,更全面地了解Akso Health Group的财务状况。

A Different Perspective


It's good to see that Akso Health Group has rewarded shareholders with a total shareholder return of 268% in the last twelve months. Notably the five-year annualised TSR loss of 13% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Akso Health Group (at least 3 which are potentially serious) , and understanding them should be part of your investment process.

很高兴看到Akso Health Group在过去十二个月中向股东提供了268%的总股东回报率。值得注意的是,五年期股东总回报率每年亏损13%,与最近的股价表现相比非常不利。长期亏损使我们保持谨慎,但短期股东总回报率的增长无疑暗示着更光明的未来。尽管市场状况可能对股价产生的不同影响值得考虑,但还有其他因素更为重要。例如,投资风险的幽灵无处不在。我们已经向Akso Health Group确定了4个警告信号(至少3个可能很严重),了解这些信号应该是您投资过程的一部分。

For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.


Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息